<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Insight4MDs</title>
	<atom:link href="http://insight4mds.com/feed/" rel="self" type="application/rss+xml" />
	<link>http://insight4mds.com</link>
	<description>Instant insight into clinical trial results</description>
	<lastBuildDate>Tue, 10 Aug 2010 15:09:23 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>A Six Month, Open Label, Randomized Parallel Group Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera) On Glycemic Control Compared To Insulin Glargine (Lantus) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Or More Oral Agents</title>
		<link>http://insight4mds.com/a-six-month-open-label-randomized-parallel-group-trial-assessing-the-impact-of-dry-powder-inhaled-insulin-exubera-on-glycemic-control-compared-to-insulin-glargine-lantus-in-patients-with-type-2-diabet/</link>
		<comments>http://insight4mds.com/a-six-month-open-label-randomized-parallel-group-trial-assessing-the-impact-of-dry-powder-inhaled-insulin-exubera-on-glycemic-control-compared-to-insulin-glargine-lantus-in-patients-with-type-2-diabet/#comments</comments>
		<pubDate>Wed, 31 Mar 2010 17:47:26 +0000</pubDate>
		<dc:creator>Dr. Viereck</dc:creator>
				<category><![CDATA[Actos]]></category>
		<category><![CDATA[Avandia]]></category>
		<category><![CDATA[Exubera]]></category>
		<category><![CDATA[Exubera Inhaler]]></category>
		<category><![CDATA[Inhaled Insulin]]></category>
		<category><![CDATA[Insulin Glargine]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[Metformin]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Phase 4]]></category>
		<category><![CDATA[Pioglitazone]]></category>
		<category><![CDATA[Rosiglitazone]]></category>
		<category><![CDATA[Sulfonylurea(s)]]></category>
		<category><![CDATA[Type 2 Diabetes]]></category>

		<guid isPermaLink="false">http://clintrialsclick.com/3821/</guid>
		<description><![CDATA[A 26 Week US Trial Comparing Exubera (Inhaled Insulin) to Lantus (Insulin Glargine)]]></description>
			<content:encoded><![CDATA[<h2 id="top"></h2>
<h2><span style="text-decoration: underline;"><strong>Table of Contents</strong></span></h2>
<ul>
<li><a href="#summary">Insight4MDs™ </a><a href="#summary">Summary </a></li>
<li><a href="#background">Background</a></li>
<li><a href="#efficacy">Efficacy Results</a></li>
<li><a href="#safety">Safety Results</a></li>
<li><a href="#pi">Prescribing Information</a></li>
<li><a href="#facts">Clinical Trial Facts</a></li>
</ul>
<h2><strong><a name="summary"></a><span style="text-decoration: underline;">Insight4MDs™ Summary</span></strong></h2>
<p>  In this 26 week phase 4 clinical trial sponsored by the drug company Pfizer, 402 patients with type 2 diabetes poorly controlled on sulfonylurea </p>
]]></content:encoded>
			<wfw:commentRss>http://insight4mds.com/a-six-month-open-label-randomized-parallel-group-trial-assessing-the-impact-of-dry-powder-inhaled-insulin-exubera-on-glycemic-control-compared-to-insulin-glargine-lantus-in-patients-with-type-2-diabet/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

